Stocks / NASDAQ / Eleven Biotherapeutics, Inc.

Eleven Biotherapeutics, Inc.

Our Opinion

Eleven Biotherapeutics, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company’s stated in its annual report 2013 that they conduct preclinical trials of their drugs on animals.

“In a live animal, or in vivo, study in a mouse model of choroidal neovascularization, we used a commercially available anti-IL-6 antibody that blocks mouse IL-6. In this study, we observed a significant reduction in abnormal neovascularization in animals treated with this anti-IL-6 antibody compared to animals that received placebo. ” (Page 23) Read the full document.

Company Description

Eleven Biotherapeutics, Inc. is a preclinical stage biopharmaceutical company engages in medical development. It involves in the management of proprietary protein engineering platform called AMP-Rx for the development and discovery of protein therapeutics to treat diseases of the eye. Through therapeutic approach, it focuses on structural biology of cytokines to design and generate product candidate called EBI-031, that targets Diabetic Macular Edema diseases. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. [Source: MarketWatch]

Company Website: